<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: <z:mp ids='MP_0002710'>Increased glucagon secretion</z:mp> predicts deterioration of <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance, and high glucagon levels contribute to <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Inhibition of glucagon action may therefore be a potential novel target to reduce <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we investigated whether <z:hpo ids='HP_0011010'>chronic</z:hpo> treatment with a glucagon receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GRA</z:e>) improves islet dysfunction in female mice on a high-fat diet (HFD) </plain></SENT>
<SENT sid="3" pm="."><plain>MATERIALS AND METHODS: After 8 weeks of HFD, mice were treated with a small molecule <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GRA</z:e> (300 mg/kg, gavage once daily) for up to 30 days </plain></SENT>
<SENT sid="4" pm="."><plain>Insulin secretion was studied after oral and intravenous administration of <z:chebi fb="105" ids="17234">glucose</z:chebi> and glucagon secretion after intravenous arginine </plain></SENT>
<SENT sid="5" pm="."><plain>Islet <z:mp ids='MP_0000002'>morphology</z:mp> was examined and insulin secretion and <z:chebi fb="105" ids="17234">glucose</z:chebi> oxidation were measured in isolated islets </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> levels were reduced by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GRA</z:e> (6.0 +/- 0.2 vs 7.4 +/- 0.5 mmol/l; p = 0.017) </plain></SENT>
<SENT sid="7" pm="."><plain>The <z:hpo ids='HP_0011009'>acute</z:hpo> insulin response to intravenous <z:chebi fb="105" ids="17234">glucose</z:chebi> was augmented (1,300 +/- 110 vs 790 +/- 64 pmol/l; p &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>The early insulin response to oral <z:chebi fb="105" ids="17234">glucose</z:chebi> was reduced in mice on HFD + <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GRA</z:e> (1,890 +/- 160 vs 3,040 +/- 420 pmol/l; p = 0.012), but <z:chebi fb="105" ids="17234">glucose</z:chebi> excursions were improved </plain></SENT>
<SENT sid="9" pm="."><plain>Intravenous arginine significantly increased the <z:hpo ids='HP_0011009'>acute</z:hpo> glucagon response (129 +/- 12 vs 36 +/- 6 ng/l in controls; p &lt; 0.01), notably without affecting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GRA</z:e> caused a modest increase in alpha cell mass, while beta cell mass was similar to that in mice on HFD + vehicle </plain></SENT>
<SENT sid="11" pm="."><plain>Isolated islets displayed improved <z:chebi fb="105" ids="17234">glucose</z:chebi>-stimulated insulin secretion after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GRA</z:e> treatment (0.061 +/- 0.007 vs 0.030 +/- 0.004 pmol islet(-1) h(-1) at 16.7 mmol/l <z:chebi fb="105" ids="17234">glucose</z:chebi>; p &lt; 0.001), without affecting islet <z:chebi fb="105" ids="17234">glucose</z:chebi> oxidation </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS/INTERPRETATION: <z:hpo ids='HP_0011010'>Chronic</z:hpo> glucagon receptor antagonism in HFD-fed mice improves islet sensitivity to <z:chebi fb="105" ids="17234">glucose</z:chebi> and increases insulin secretion, suggesting improvement of key defects underlying <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>